When Paragraph IV filings hit the docket, they set off a chain of financial events most analysts only half-understand. Here […]

Every pharmaceutical analyst knows when the compound patent expires. It is on the Bloomberg terminal, in the 10-K, in every

The average branded drug reaches pharmacy shelves with roughly 10 to 12 years of effective patent life remaining. The average

The $200 billion patent cliff bearing down on Big Pharma through 2030 is not primarily a manufacturing or regulatory problem.

The patent cliff is not a metaphor. When Humira’s U.S. composition-of-matter patent finally cracked open in 2023, AbbVie had already

A single composition-of-matter patent can represent $40 billion in franchise value. At the Patent Trial and Appeal Board (PTAB), that

A Paragraph IV filing is not a legal emergency. It is a predictable business event built into the architecture of

Pharmaceutical value is not built exclusively in the laboratory. It is won and lost on the global chessboard of intellectual

KSR killed your obviousness defense. Amgen killed your functional claims. Here is the complete IP architecture for winning anyway, from